Tie-1 Activators belong to a distinct chemical class characterized by their ability to modulate the Tie-1 receptor, which is a member of the Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor Homology Domains (TIE) receptor family. Tie-1, along with its closely related counterpart Tie-2, plays a crucial role in regulating vascular development and stability. Tie-1, however, has been historically considered an orphan receptor due to its elusive ligands and unclear function. Recent research has shed light on Tie-1's role in fine-tuning angiogenesis and vascular homeostasis. Tie-1 Activators are compounds specifically designed to interact with this receptor and influence its signaling pathways.
The Tie-1 receptor is predominantly expressed in endothelial cells within the vascular system. Activation of Tie-1 is thought to be involved in maintaining vascular integrity by modulating the response to angiogenic signals and inflammatory cues. Tie-1 Activators can either enhance or inhibit Tie-1 signaling, depending on their chemical structure and mode of action. These compounds have gained attention in the field of vascular biology for their ability to regulate blood vessel formation and remodeling, making them valuable tools for researchers seeking to better understand the complexities of angiogenesis and vascular development. While Tie-1 Activators are still a subject of ongoing research, their precise mechanisms of action and downstream effects on vascular biology continue to be explored.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, another kinase inhibitor, potentially influences Tie-1 activity through its anti-angiogenic effects. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib, another multi-kinase inhibitor, could indirectly impact Tie-1 through its broad spectrum of target kinases. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib, a multi-kinase inhibitor, may have indirect implications for Tie-1 through its anti-angiogenic properties. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
Lenvatinib, another multi-targeted tyrosine kinase inhibitor, might influence Tie-1 signaling indirectly. | ||||||
Apatinib | 811803-05-1 | sc-480044 | 10 mg | $380.00 | ||
Apatinib, targeting VEGFR, can have secondary effects on Tie-1 activity, given its role in angiogenesis. | ||||||